|
Originally published In Press as doi:10.1074/jbc.M202522200 on June 21, 2002
J. Biol. Chem., Vol. 277, Issue 36, 33188-33195, September 6, 2002
The Adenosine 2b Receptor Is Recruited to the
Plasma Membrane and Associates with E3KARP and Ezrin upon Agonist
Stimulation*
Shanthi V.
Sitaraman §¶,
Lixin
Wang ,
Michelle
Wong ,
Matthias
Bruewer ,
Michael
Hobert ,
C-H.
Yun§,
Didier
Merlin , and
James L.
Madara
From the § Division of Digestive Diseases, Department of
Medicine, the Epithelial Biology Unit, Department of
Pathology, and Emory University, Atlanta, Georgia 30322
Received for publication, March 15, 2002, and in revised form, May 31, 2002
 |
ABSTRACT |
We have previously shown that adenosine is
formed in the intestinal lumen during active inflammation from
neutrophil-derived 5'-AMP. Acting through the adenosine A2b receptor
(A2bR), the luminally derived adenosine induces vectorial chloride
secretion and a polarized secretion of interleukin-6 to the intestinal
lumen. Although some G protein-coupled receptors interact with
anchoring or signaling molecules, not much is known in this critical
area for the A2bR. We used the model intestinal epithelial cell line, T84, and Caco2-BBE cells stably transfected with GFP-A2b receptor to
study the intestinal A2bR. The A2bR is present in both the apical and
basolateral membranes of intestinal epithelia. Apical or basolateral
stimulation of the A2bR induces recruitment of the receptor to the
plasma membrane and caveolar fractions. The A2bR co-immunoprecipitates
with E3KARP and ezrin upon agonist stimulation. Ezrin interacts with
E3KARP and PKA and the interaction between ezrin and E3KARP is enhanced
by agonist stimulation. Our data suggest that the A2bR is recruited to
the plasma membrane upon apical or basolateral agonist stimulation and
interacts with E3KARP and ezrin. We speculate that such an interaction
may not only anchor the A2bR to the plasma membrane but may also
function to stabilize the receptor in a signaling complex in the plasma membrane.
 |
INTRODUCTION |
Adenosine is an ubiquitous extracellular signaling molecule that
is released during inflammation and acts as a paracrine factor with
diverse effects on the inflammatory cascade (1-7). In the intestine,
neutrophil transmigration into the lumen to form crypt abscesses is the
pathologic hallmark of the active phase of many intestinal disorders,
including inflammatory bowel disease. We have previously shown that
neutrophils, upon transmigration into the intestinal lumen, release
5'-AMP (8, 9). Adenosine is derived from 5'-AMP when it is converted by
the intestinal apical membrane 5'-ectonucleotidase (CD 73) (11) and can
subsequently interact with the intestinal adenosine receptor (10). The
adenosine receptor belongs to the family of the G protein-coupled group of cell surface receptors (12, 13). On the basis of initial pharmacological criteria, adenosine is known to interact with one of
the four adenosine receptor subtypes A1, A2a, A2b, and A3 (3, 4, 12,
13), all of which have now been cloned. Using molecular, pharmacologic,
and biochemical approaches we characterized the intestinal adenosine
receptor as the A2b subtype in both T84 cells, a model intestinal
epithelial cell line, and intact human intestinal epithelia (10).
Furthermore, the A2bR appears to be the only adenosine receptor present
in T84 cells (10, 14). In these cells, the A2bR is functionally coupled to G s and the stimulation of the apical or basolateral
surface with adenosine results in cAMP-mediated vectorial chloride
secretion (9, 10, 15-17) and interleukin-6 synthesis and
secretion (18).
The distribution and coupling of A2bR upon agonist stimulation with
cytoplasmic structural proteins and the potential significance of this
is not known. On the basis of effective coupling of minute second
messenger signals to protein kinase A
(PKA)1 we hypothesized
sometime ago that A2bR might be compartmentalized with signaling
molecules and their targets (10). Huang et al. (19) recently
provided functional evidence for such an organized complex including
G s; adenylate cyclase, PKA, and CFTR are
compartmentalized in microdomains in the apical plasma membrane. Such
compartmentalization of signaling networks in a multiprotein complex
has been shown to result in both the stabilization of constituent
proteins at the cell surface and enhanced efficiency of signaling (20). A common mechanism for establishing multiple protein complexes is via
protein-protein interaction with submembrane scaffolding proteins.
PSD-95/Dlg/ZO-1 (PDZ) domain proteins localized to the membrane-cytoskeletal interface have emerged as important organizing centers for regulatory complexes, and these scaffold-based regulatory proteins are often polarized to specific sites in polarized epithelial cells (20, 21). For example, ERM (ezrin-radixin-moesin)-binding protein
(EBP50 or NHERF-1) and its related homolog NHE-3 kinase regulatory
proteins (E3KARP or NHERF-2) appear to coordinate specific cAMP-mediated secretory responses (21). The PDZ interacting motif
(S/T)XL at the C terminus of proteins such as
-adrenergic receptor (22) and CFTR (23), binds to NHERF, which in
turn interacts with ezrin. Ezrin is known to act as a protein kinase A
anchoring protein (21) in addition to associating with the actin
cytoskeleton (reviewed in Ref. 24). The interaction between NHERF,
ezrin, and PKA has been shown to be critical for the functional response of transporters including CFTR (21) and NHE-3 (25).
In this study we examined the association of A2bR at rest and after
stimulation with E3KARP, ezrin, and PKA. We show that the A2bR is
recruited to the plasma membrane fraction upon stimulation with
adenosine. The recruitment of the A2bR to the membrane is paralleled by
its interaction with E3KARP and ezrin. Ezrin directly interacts with
the A2bR and is activated in response to adenosine stimulation. Taken
together, our data suggest that the A2bR, and its signaling complex,
exists in the microdomain in the membrane, and adenosine signaling
through the A2bR may be mediated by such close interaction and
recruitment of the receptor to the membrane.
 |
Materials and Methods |
Reagents--
All tissue culture supplies were obtained from
Invitrogen. Adenosine and
5'-(N-ethylcarboxamido)adenosine were obtained from Research
Biochemicals Int. (Natick, MA). Reagents for SDS-PAGE and
nitrocellulose membranes (0.45-µm pores) were from Bio-Rad. Anti-A2bR
antibody was obtained from Alpha Diagnostics Inc. (San Antonio, TX),
anti-NHERF antibodies were obtained from Dr. Yun (Emory University,
GA), and mouse monoclonal anti-CD 73 was a gift from Dr. Thompson
(University of Oklahoma). Anti-ezrin antibody was obtained from Sigma;
anti-caveolin 1, anti- 1 integrin, and anti-GFP
were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Other antibodies include fluorescein isothiocyanate-labeled goat
anti-rabbit antibody and horseradish peroxidase-conjugated Ig were
obtained from Jackson ImmunoResearch Laboratory (West Grove, PA) and
Amersham Biosciences, respectively.
Cell Culture--
T84 cells were grown and maintained in culture
as previously described (8) in a 1:1 mixture of Dulbecco's modified
Eagle's medium and Ham's F-12 medium supplemented with penicillin (40 mg/liter), ampicillin (8 mg/liter), streptomycin (90 mg/liter), and 5%
newborn calf serum. Confluent stock monolayers were subcultured by
trypsinization. Experiments were done on cells plated for 7-8 days on
permeable supports of 0.33 cm2 or 4.5 cm2
(inserts). Inserts with rat tail collagen-coated polycarbonate membrane
filter (0.4-µm pore size, Costar, Cambridge, MA) rested in wells
containing media until steady-state resistance was achieved, as
previously described (8). This permits apical and basolateral membranes
to be separately interfaced with apical and basolateral buffer, a
configuration identical to that previously developed for various
microassays (8). The T84 cells had a high electrical resistance
(1200-1500 cm2). All experiments were performed on T84
cells between passages 69 and 83. Caco2-BBE were grown as confluent
monolayers in a 1:1 mixture of Dulbecco's modified Eagle's medium and
Ham's F-12 medium supplemented with 15 mM HEPES buffer, pH
7.5, 14 mM NaHCO3, and 10% newborn calf serum.
Transfected cell lines were maintained in the same media
containing 1.2 mg/ml G418. Cell surface biotinylation studies were
carried out with confluent monolayers plated on collagen-coated permeable supports. CHO cells (ATCC) were grown in Dulbecco's modified
Eagle's medium containing 10% fetal bovine calf serum supplemented
with penicillin and streptomycin.
Transfections--
Full-length A2bR cDNA was cloned into the
pEGFP-C vector (CLONTECH) using HindIII
and BamHI restriction enzymes. Point mutation was introduced
into the stop codon of the wild-type human A2bR cDNA (sense primer:
CGGTGTGGGCCTACTCAGTTAGGCTCTCG and antisense primer:
CGAGAGCCTAGACTGAGTAGGCCCACACCG) by site-directed mutagenesis using
PCR-mediated overlap extension to facilitate fusion of the cDNA
sequence using the QuikChange site-directed mutagenesis kit (Stratagene). The constructed plasmid cDNA sequences were verified by sequencing. Plasmids were purified using the Qiagen Maxiprep kit.
Subconfluent Caco2-BBE cells were transfected with A2b-GFP vector using
Lipofectin (Invitrogen) for 20 h in serum-free medium. Serum was
added for the subsequent 48 h and stable transfectants were
selected in medium containing 1.2 mg/ml G418. The 10 clones selected
from each construct were maintained in 1.2 mg/ml G418 and were
expanded. Clones showing the highest expression were generated by
repeated sorting of fluorescent clones using fluorescence-activated cell sorter. PRK vector containing full-length A2bR was a generous gift
from R. J. Mrsny (Genentech Inc., San Francisco, CA).
Confocal Microscopy--
Monolayers of T84 or Caco2-BBE cells
were washed in HBSS, fixed in buffered formaldehyde for 20 min,
incubated with the respective primary antibodies overnight in a
humidity chamber, washed with HBSS, and subsequently incubated with
fluorsceinated secondary antibodies (Jackson ImmunoResearch).
Monolayers were also counterstained with rhodamine/phalloidin to
visualize actin. Monolayers, mounted in
p-phenylenediamine/glycerol (1:1) were analyzed by confocal microscopy (Zeiss dual laser confocal microscope) as described (18). In
the case of Caco2-BBE cells transfected with GFP containing vector,
monolayers were directly fixed, stained with rhodamine/phalloidin, mounted on glass slides, and analyzed by confocal microscopy. Using
actin staining, the apical most surface of the cell was marked as 0 µm and the basolateral surface was marked at the level of actin
stress fiber (~18.7 µm from the top of the cell). xy sections taken at ~1.2 µm from the top (above the level of tight junction) and at the level of actin stress fiber was used for quantitation of apical and basolateral surfaces, respectively.
SDS-PAGE and Western Blot--
Cells were lysed with
phosphate-buffered saline containing 1% Triton X-100 and 1% Nonidet
P-40 (v/v), protease inhibitor mixture (Roche Molecular Biochemicals),
EDTA, SDS, sodium orthovanadate, and sodium fluoride. SDS-PAGE was
performed according to the Laemmli procedure using a 10% acrylamide
gel. Proteins were electrotransferred to nitrocellulose membranes and
probed with primary antibody (diluted 1:1000). Then membranes were
incubated with corresponding peroxidase-linked secondary antibody
diluted 1:2000, washed, and subsequently incubated with ECL reagents
(Amersham Biosciences) before exposure to high performance
chemiluminescence films (Amersham Biosciences). For Mr determination, polyacrylamide gels were
calibrated using standard proteins (Bio-Rad) with Mr
markers within the range 7,700 to 214,000.
Cell Surface Biotinylation and Immunoprecipitation--
Apical
or basolateral sides of the filter-grown monolayers were biotinylated
using sulfosuccinimidyl-biotin (s-NHS-biotin, Pierce, Rockford,
IL) as previously described (26). The cell lysate was then incubated
with streptavidin-agarose (Pierce) to bind biotinylated proteins.
Proteins were separated by SDS-PAGE and Western blotting was done as
described previously (26)
Isolation of Plasma Membrane and Caveoli--
Cell fractionation
to isolate pure plasma membrane and caveolae was done as described (27)
using a detergent-free method. Briefly, confluent T84 monolayers grown
in 45-cm2 inserts were washed with HBSS, equilibrated for
20 min at 37 °C, and stimulated with apical or basolateral adenosine
(100 µM). A plasma membrane fraction was prepared from
two 4.5-cm2 inserts/condition. The plasma membrane fraction
obtained by this method, as previously shown, was not contaminated with
cytoplasm or membranes from other compartments. This approach was
chosen because the detergent solubility of some proteins such as the subunit of heterotrimeric G-proteins or certain G protein-coupled receptors is well established. Caveolae were purified from the plasma
membrane fraction using Opti-Prep gradient (27).
Flow Cytometry--
Adherent monolayers were detached with EDTA
in HBSS (without Ca2+ or Mg2+), pelleted by
centrifugation, and re-suspended in HBSS containing 1% bovine serum
albumin. Cells transfected with GFP-tagged A2bR were directly analyzed
with FAC-Sort flow cytometer apparatus (BD PharMingen) as described
(28).
cAMP Measurements--
Measurements of cAMP were performed on
ethanol extracts of cells obtained from monolayers grown on
permeable supports, using the radioimmunoassay kit as described by the
supplier (PerkinElmer Life Sciences). Briefly, after monolayers
were washed with HBSS and incubated 10 min, baseline Isc
readings were taken and then adenosine was added. Cells were lysed in
the extract buffer (66% ethanol, 33% HBSS, 1 mM
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine). Monolayers
were compacted, centrifuged, and an aliquot (100 µl) was used for
radioimmunoassay (10).
Quantitation of Western Blot and Confocal Images--
The band
intensity of Western blot was quantitated using a gel documentation
system (Alpha Innotech Co., San Leandro, CA). Quantitation of confocal
images were performed on unprocessed images using the Metamorph Imaging
System software (Universal Imaging Corp., West Chester, PA) as
described (29). The average grayscale pixel intensity +1 S.D. of a
small region was measured and defined as background. To subtract
background, the threshold of each channel was set at the value obtained
for background. The average pixel intensity +1 S.D. was measured for
the threshold images. The data are presented as the mean ± S.D.
Statistical analysis was performed using unpaired Student's
t test. p value < 0.05 was considered
statistically significant.
 |
RESULTS |
A2bRs Are Present in Both the Apical and Basolateral Membranes of
Intestinal Epithelial Cells and in the Transfected Intestinal Cell
Line--
We first characterized the commercially available antibody
to the second extracellular loop of the A2bR. T84 cells, which we have
shown previously express the A2bR, exhibited an immunoreactive band at
42-44 kDa (Fig. 1, lane 2).
In addition, membrane fractions from HEK 293 cells overexpressing A2bR
also showed a similar immunoreactive band at 42-44 kDa (Fig. 1,
lane 1). The immunoreactive band was competed by peptide
used to raise the antibody (data not shown). CHO cells, which lack
expression of A2bR mRNA and cAMP response to agonist stimulation,
showed no immunoreactivity at 42-44 kDa (Fig. 1, lane 4)
and as seen in lane 3, CHO cells transfected with
full-length A2bR showed an immunoreactive band at 42-44 kDa similar to
that seen in T84 cells and HEK 293 cells. These data demonstrate that
the antibody specifically recognizes the 42-44-kDa A2bR.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1.
Specificity of anti-A2b antibody. Whole
cell detergent lysates were prepared from T84 monolayers (lane
2) and CHO cells stably transfected with PRK vector alone
(lane 4) or with PRK-A2bR (lane 3). Membranes
from HEK cell lines overexpressing A2bR (lane 1) were
purchased from Sigma. Whole cell detergent lysates (20 µg of
protein/lane) were resolved by SDS-PAGE and immunoblotted for A2bR
using anti-A2b antibody.
|
|
We next examined the polarity of the A2bR. Using cell surface
biotinylation, we show that the A2bR is present at both the apical and
basolateral membranes of the model intestinal epithelial cells.
However, as shown in Fig. 2A,
the A2bR expression is significantly higher at the basolateral membrane
compared with the apical membrane (apical:basolateral ratio, 1:3.1 ± 0.9, mean ± S.D., n = 6, p < 0.001). CD 73, an apically expressed protein (11), showed an
apical:basolateral ratio of 5 ± 0.9:1 (mean ± S.D.,
n = 3, p < 0.01), whereas
1 integrin, a basolaterally expressed protein (30)
showed an apical:basoateral ratio of 1:7 ± 0.5 (relative band
density mean ± S.D., n = 3, p < 0.001) (Fig. 2B). Next we examined the distribution of A2bR
using confocal microscopy (Fig. 3).
Consistent with our data on cell surface biotinylation, the A2bR is
expressed both at the apical and basolateral surface of T84 cells (Fig.
3A). The en face (xy plane) images of
the T84 epithelia were taken at the apical and basolateral membranes. To quantitate the cell surface expression of A2bR, the pixel intensity of the confocal images taken at the apical and basolateral surfaces were measured as described under "Materials Methods." As seen in
Fig. 3B, the ratio of pixel intensity of apical:basolateral A2b receptor was 1:1.7 ± 0.2 (relative units mean ± S.D.,
n = 8, p < 0.001) compared with the CD
73 and 1 integrin apical:basolateral ratio of 5 ± 0.2:1 and 1:3 ± 0.3, respectively (relative units, mean ± S.D., n = 3, p < 0.01).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
A2bR is expressed at both the apical and
basolateral membranes. A, filter-grown monolayers were
subjected to cell surface biotinylation (lane 1, Ap apical
domain; lane 2, Bs basolateral domain) for 30 min followed
by immunoprecipitation with avidin beads. Immunoprecipitates were
subjected to Western blot and detected with anti-A2b antibody, anti-CD
73, or anti- 1 integrin (int). B,
the intensity of bands from panel A was quantitated as
described under "Materials and Methods." The bar graphs
represent relative band intensity apical (A)
versus basolateral (B) membrane, mean ± S.D. *, p < 0.001; **, p < 0.01.
|
|

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 3.
Confocal microscopy of A2bR.
A, monolayers were fixed and stained with anti-A2b antibody
followed by fluoroscein isothiocyanate-conjugated secondary antibody
(A2bR, anti-CD 73, or anti- 1
integrin; green). Monolayers were also stained
with rhodamine/phalloidin (actin, red). Vertical
sections (xz) were taken off the monolayers to define the
top (set at 0 µm) and bottom of the monolayer. En face
sections (xy) were then generated from apical and
basolateral planes in the vertical section. Shown here are en
face (xy) images taken at the level of apical (at 1.2 µm, above
the level of tight junction) and basolateral (at 18.7 µm, level of
stress fiber) pole of the epithelial monolayer and computer
reconstructed vertical section (xz) images taken through
full thickness of the monolayer. B, the pixel intensity from
panel A was quantitated as described under "Materials and
Methods." The bar graphs represent the relative pixel
intensity apical (A) versus basolateral
(B) membrane, mean ± S.D.; *, p < 0.001; **, p < 0.01.
|
|
Based on its cDNA sequence, A2bR is predicted to have a molecular
mass of 36 kDa. However, our data suggest that the A2bR in T84 cells is
42-44 kDa. To verify the molecular mass of the A2bR in intestinal
epithelial cells we stably transfected the intestinal cell line,
Caco2-BBE, with GFP-tagged A2bR. As shown in Fig.
4A, GFP-A2b-transfected
Caco2-BBE cells show a shift in fluorescence compared with
untransfected cells demonstrating a high level of fusion-protein
expression. We then used an anti-GFP antibody to immunoprecipitate the
GFP-A2bR fusion protein from whole cell lysates and detected the A2bR
on a Western blot using anti-A2bR antibodies. As seen in Fig.
4B, transfected cells exhibit a ~68-70-kDa band
corresponding to the GFP-A2bR fusion protein. This band was not present
in the wild-type Caco2-BBE cells or in cells transfected with GFP
vector alone (lanes 1 and 2, respectively). The
GFP-A2b fusion protein expression was enhanced after the second and
third round of fluorescence-activated cell sorting of fluorescent clones (lanes 3 and 4, respectively). We next
determined the steady-state distribution of GFP-A2bR fusion protein
expression using cell surface biotinylation. Similar to the T84 cells,
the A2bR was present at both the apical and basolateral surface but
predominant at the basolateral surface (apical to basolateral ratio of
1:6 ± 0.5, relative units from a densitometric scan, mean ± S.D., n = 3, p < 0.003) (Fig.
4C). CD 73, an apically expressed protein in Caco2-BBE cells
(11, 31), showed an apical:basolateral ratio of 5 ± 0.9:1,
whereas 1 integrin (30) showed an apical:basoateral ratio of 1:6 ± 0.3 (relative units from densitometric scan,
mean ± S.D., n = 3, p < 0.01 and
p < 0.001, respectively, data not shown). Confocal
images of transfected Caco2-BBE cells also show the expression of the
A2bR at the apical and basolateral surface (Fig. 4D). To
quantitate the cell surface expression of GFP-A2bR, the pixel intensity
of the confocal images taken at the apical and basolateral surfaces
were measured. The ratio of pixel intensity of apical:basolateral A2b
receptor was 1:3 ± 0.5 (relative pixel units, mean ± S.D.,
n = 3, p < 0.01). CD 73 and
1 integrin showed an apical:basolateral ratio of
4.6 ± 0.6:1 and 1:3.8 ± 0.2, respectively (relative pixel
units, mean ± S.D., n = 3, p < 0.005 and p < 0.001, respectively, data not shown). To
determine whether the GFP-A2bR fusion protein was functional, the cells
were stimulated with adenosine and intracellular cAMP was measured 5 min after stimulation. Apical or basolateral stimulation of
GFP-A2bR-transfected cells with adenosine induced an 8-fold increase in
cAMP compared with cells transfected with vector alone (Fig.
4E). These data demonstrate that Caco2-BBE cells transfected
with GFP-tagged A2bR has a similar molecular mass as the endogenous
A2bR in T84 cells.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Expression of GFP-tagged A2bR in Caco2-BBE
cells. A, analysis of transfectants by flow cytometry:
untransfected Caco2-BBE cells (black histogram) or those
with GFP-fused to A2bR after cell sorting of the highly fluorescent
clones (open histogram). B, whole cell lysates
from wild-type Caco2-BBE cells (lane 1), GFP vector
(lane 2), or GFP-A2bR transfected cells (lane 3 prior to cell sorting for fluorescent clone and lane 4 post-sorting of stable transfectants) were subjected to
immunoprecipitation with anti-GFP antibody and detected with anti-A2b
antibody on a Western blot of the immunoprecipitates. C,
filter-grown GFP-A2b transfected Caco2-BBE cells were subjected to
domain-specific biotinylation (lane 1, Ap,
apical; lane 2, Bs, basolateral). Biotinylated
proteins were immunoprecipitated with avidin beads and subjected to
Western blot and immunostained using anti-A2b antibody. Also shown in
the bar graph is the relative band intensity of apical
versus basolateral membrane, mean ± S.D.;
n = 3; *, p < 0.001. D,
confocal microscopic localization of GFP-A2bR (green) in
transfected cells (xy) and computer-reconstructed vertical
section (xz) images taken through the full thickness of the
monolayer. Monolayers were also stained with rhodamine/phalloidin
(actin, red). E, GFP vector or
GFP-A2b-transfected cells were stimulated with apical or basolateral
adenosine (100 µM) for 5 min. cAMP was determined in cell
lysates as described under "Materials and Methods." Representative
data from two individual experiments using two samples/condition are
shown.
|
|
A2bR Is Recruited to the Plasma Membrane Fractions upon Apical or
Basolateral Stimulation of the A2bR--
Having established the
specificity of the antibody to the native receptor in T84 cells, we
next studied the effect of agonist stimulation on the distribution of
A2bR. Since Caco2-BBE cells are known to possess more than one type of
adenosine receptor, T84 cells in which A2bR is the only adenosine
receptor present were used to further characterize the A2bR. As seen in
Fig. 5, there was a small amount of A2bR
detected in the plasma membrane fraction in resting cells and the bulk
of the receptor was present in the postnuclear supernatant. In
contrast, receptor density was significantly increased in the plasma
membrane 5 min after apical or basolateral stimulation with adenosine
(control:apical stimulation, 1:7.4 ± 0.4; control:basolateral
stimulation, 1:7.9 ± 0.6 relative units from densitometric scan,
mean ± S.D., n = 3 p < 0.001).
The caveolar fraction contained A2bR at rest and there was a mild but
significant increase in this fraction after apical or basolateral
stimulation (control:apical stimulation, 1:1.9 ± 0.3;
control:basolateral stimulation, 1:1.5 ± 0.05 relative units from
densitometric scan, mean ± S.D., n = 3, p < 0.01 and p < 0.001, respectively). As expected, caveolin was enriched in the caveolar
fraction (postnuclear:plasma membrane:caveoli, 1:1.8 ± 0.2:7.2 ± 0.1 in unstimulated monolayers, relative units from densitometric scans, mean ± S.D., n = 3, p < 0.001 plasma membrane and caveolar fraction
compared with the postnuclear supernatant). Apical or basolateral
adenosine did not have any effect on the distribution of caveolin in
these fractions (postnuclear:plasma membrane:caveoli apical adenosine,
1:1.8 ± 0.1:7.0 ± 0.3; basolateral adenosine, 1:2.0 ± 0.01:6.9 ± 0.2, relative units from densitometric scan, mean ± S.D., n = 3). These data demonstrate that apical or
basolateral stimulation with adenosine results in the recruitment of
A2bR to the plasma membrane and, to a lesser extent, to the caveolar
fraction.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Adenosine induces recruitment of A2bR to
plasma membrane fraction. T84 monolayers were washed with HBSS,
equilibrated for 20 min at 37 °C, and stimulated with adenosine (100 µM, apical or basolateral) for 5 min. T84 cells were
subfractionated as described under "Materials and Methods." The
amount of protein in each subcellular fraction was determined and 5 µg of protein from each subcellular fraction (caveoli and plasma
membrane) and 10 µg of postnuclear supernatant was resolved by
SDS-PAGE and immunoblotted for A2bR and caveolin-1. Cav,
caveolar membrane; P.M., plasma membrane; P.N.,
postnuclear supernatant. Representative data observed in three separate
experiments is shown. Bar graphs for A2bR represent the fold
increase in band intensity of apical (A) or basolateral
(B) stimulation compared with unstimulated monolayers,
mean ± S.D.; n = 3; *, p < 0.001; **, p < 0.01. Bar graphs for
caveolin represent relative band intensity of postnuclear, plasma
membrane, and caveolar fraction C (control), A
(apical stimulation), and B (basolateral stimulation),
mean ± S.D.; n = 3; *, p < 0.001, compared with caveolin in postnuclear supernatant.
|
|
The A2bR Associates with the PDZ-domain Containing Proteins, E3KARP
and Ezrin--
NHERF and E3KARP are subplasma membrane PDZ domain
proteins that may serve to anchor membrane proteins such as CFTR to the cytoskeleton. NHERF and E3KARP are thought to work in concert with
ezrin and PKA to bring a signaling complex in close proximity to
membrane proteins, such as CFTR enhancing efficiency and stabilizing proteins in the membrane. To determine whether the PDZ domain protein
may regulate A2bR membrane organization, we examined whether NHERF was
associated with A2bR. As shown in Fig.
6A, E3KARP
co-immunoprecipitated with the A2bR. This association was apparent 5 min after apical or basolateral adenosine stimulation and was barely
detectable in resting cells (unstimulated:apical adenosine, 1:1.9 ± 0.1; and unstimulated:basolateral adenosine, 1:2.1 ± 0.05, relative band intensity, mean ± S.D., n = 3, p < 0.03). The A2bR also co-immunoprecipitated with
ezrin after apical or basolateral stimulation for 5 min with adenosine
(Fig. 6B). The coimmunoprecipitation of the A2bR with ezrin
after receptor stimulation was 4-fold higher than that of the
immunoprecipitate obtained in control cells (unstimulated:apical adenosine, 1:4 ± 0.2; unstimulated:basolateral adenosine,
1:4.5 ± 0.9, relative band intensity, mean ± S.D.
n = 3, p < 0.001 unstimulated compared
with apical or basolateral stimulation, respectively). In addition, as
shown in Fig. 6C, apical or basolateral stimulation of the
A2bR enhanced the interaction between E3KARP and ezrin (unstimulated:apical adenosine, 1:3 ± 0.1;
unstimulated:basolateral adenosine, 1:3 ± 0.1, relative band
intensity, mean ± S.D., n = 2, p < 0.01 unstimulated compared with apical or basolateral adenosine,
respectively). However, the interaction of ezrin with PKA RII was
not affected by adenosine stimulation (Fig. 6D)
(unstimulated:apical stimulation, 1:1.3 ± 0.4;
unstimulated:basolateral adenosine stimulation, 1:1.4 ± 0.5, relative band intensity, mean ± S.D., n = 3, NS). These data demonstrate that the A2bR interacts with E3KARP and ezrin.
Consistent with the data in the literature, ezrin associates with
E3KARP and PKA RII- . The interaction between A2bR and ezrin and
ezrin and E3KARP were significantly enhanced upon stimulation with
adenosine.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
Interaction between A2bR and E3KARP, ezrin,
and PKA. T84 cells were washed with HBSS, equilibrated for 20 min
at 37 °C, and stimulated with adenosine (100 µM,
apical (ap) or basolateral (bs) for 5 min
(lane 1, unstimulated; lane 2, ap adenosine;
lane 3, bs adenosine). A, immunoprecipitates
obtained with E3KARP antibody from T84 cell lysates were separated on
SDS-PAGE, transferred to polyvinylidene difluoride membrane, and
probed with a polyclonal anti-A2bR (anti-A2b). B,
immunoprecipitates obtained with monoclonal ezrin antibody were
immunoblotted with polyclonal anti-A2b antibody. C,
immunoprecipitates obtained with monoclonal anti-ezrin antibody were
immunoblotted with polyclonal anti-A2b antibody; D,
immunoprecipitates obtained with monoclonal ezrin antibody were
immunoblotted with polyclonal anti-PKA RII . As a negative control,
immunoprecipitation was performed using irrelevant mouse IgG
(lane 0). The results represent three separate experiments.
E, bar graph represents fold increase in
band intensity of apical (2) or basolateral (3)
adenosine stimulation compared with unstimulated monolayers shown in
panels A-D, respectively. Values represent
mean ± S.D.; n = 3; *, p < 0.001; **, p < 0.03.
|
|
 |
DISCUSSION |
In this study we used the human intestinal epithelial cell
line T84 to examine the distribution and association of A2bR to its
signaling repertoire in response to agonist stimulation. The cell line
used, T84, was previously used to identify mechanisms of
neutrophil-derived 5'-AMP conversion to adenosine (CD 73), identify
A2bR as the only adenosine receptor, and define its signaling mechanism
(cAMP). These observations were subsequently shown to accurately
predict events in natural human intestinal epithelia (9-11, 14). In
this study we first verified the specificity of the anti-A2bR antibody.
The antibody gives an immunoreactive band at 42-44 kDa in T84 cells,
CHO cells transfected with full-length A2bR, and HEK 293 membranes
overexpressing A2bR. This immunoreactive band was not present in
untransfected CHO cells or Caco2-BBE cells. In addition, using GFP-A2b
fusion protein we show that immunoreactivity at 68-70 kDa corresponds
to the GFP-A2bR fusion protein. Furthermore, using
anti-hemagglutinin and anti-V5 antibodies, we demonstrate that
CHO cells transfected with hemagglutinin- or V5-tagged A2bR also gives
an immunoreactive band at 40-44 kDa similar to that observed in T84
cells (data not shown). These results establish that the anti-A2b
antibody specifically recognizes the A2bR. Our data is in agreement
with others who, using antibody to another epitope in the A2bR,
observed that the A2bR had a similar molecular mass of 42 kDa (32, 33)
in human lymphocytes and CHO cells transfected with the native
receptor. The A2bR is known to have two promoters and in addition, a
pseudogene located on chromosome 1 (34). Alternate splicing resulting
in protein sequence heterogeneity similar to that observed in several
other receptors such as dopamine receptor; EP3 receptor has been
proposed for the A2bR (3). This may explain the discrepancy in the
molecular mass observed in our study compared with a predicted
molecular mass of 36 kDa (35).
We used the anti-A2b antibody to further characterize the A2bR in the
model intestinal epithelia. We and others have previously shown
that A2b is the only adenosine receptor present in T84 cells and in
intact human intestinal epithelia (10, 14, 36). Here we show that the
A2bR is present at both the apical and basolateral membranes of T84
cells. Cell surface biotinylation studies show a more prominent
expression of the A2bR at the basolateral surface compared with apical
surface. We and others have shown that for the same amount of Isc by
adenosine, basolateral stimulation gives 10-20-fold greater cAMP
compared with apical stimulation (10, 15, 16). The higher receptor
density at the basolateral membrane may explain the robust cAMP
response to basolateral adenosine stimulation.
Our data show that apical or basolateral stimulation of the A2bR
results in increased receptor expression in the plasma membrane fraction. Such recruitment and movement of receptor in and out of the
membrane microdomain is known to occur for other G protein-coupled receptors including adenosine A1 receptor (37) and transporters including CFTR (38-40).
In addition to receptor density, the disparate cAMP response of apical
versus basolateral adenosine stimulation compared with the
Isc response (10) may also be explained by the presence of A2bR and its
signaling complex in close proximity to the cAMP-dependent Cl channels in the apical membrane. Thus, signal
transduction via apical adenosine receptor may occur at low receptor
occupancy (ED50 > 10-fold lower) via efficient coupling to
adenylate cyclase, protein kinase A, and Cl conductance pathways. Such
efficiency may reflect the close spatial relationship between
the components of this putative signal-transducing pathway (10). Indeed
recent data using patch clamp experiments in isolated apical membrane are in agreement with this hypothesis (19). Our findings provide structural evidence that the A2bR upon apical or basolateral agonist stimulation is present in a multiprotein complex. We demonstrate protein-protein association between A2bR and E3KARP and ezrin, ezrin
and E3KARP and PKA RII . Along with our data demonstrating the
recruitment of the A2bR to the plasma membrane fraction, these data
suggest that the A2bR may be anchored in the plasma membrane by E3KARP.
The A2bR, through activation of ezrin, may thus bring PKA in close
proximity to adenylate cyclase and CFTR. Ezrin on the one hand
interacts with actin cytoskeleton and on the other hand functions as a
PKA anchoring protein bringing it in close proximity to the receptor
signaling complex (21, 25). Similar interaction between NHERF and the G
protein-coupled receptor has been noted for the
2-adrenergic receptor (22).
We are currently exploring the mechanism by which A2bR interacts with
E3KARP. In the case of the 2-adrenergic receptor, the interaction between the receptor and NHERF was shown to be mediated by
the PDZ-binding (S/T)XL motif in the C terminus of the
2-adrenergic receptor that directly interacts with NHERF
(22). The authors also showed that such an interaction was not
necessary for the coupling of the 2-adrenergic receptor
to G-proteins but was essential for the receptor-mediated inhibition of
the Na+/H+ exchanger (22). Although the A2bR
does not contain the consensus PDZ-binding motif in the classical C
terminus location, the sequence is present in the third intracellular
loop. Such interaction between NHERF-1/E3KARP and the PDZ-interacting
motif in atypical locations has been observed for NHE3-NHERF
interaction (25). Whether or not the interaction of A2b receptor with
E3KARP, ezrin, and PKA is necessary for G-protein coupling or chloride
secretion needs to be determined. Our preliminary data shows that the
cAMP response to adenosine stimulation is attenuated in Caco2-BBE cells
transfected with a GFP-tagged A2bR containing a valine alanine
mutation in the PDZ consensus motif in the third extracellular
loop.2
Our data demonstrate that the A2bR interacts with ezrin and the
interaction of ezrin with both E3KARP and A2bR is at least 3-fold
greater upon stimulation of the A2bR suggesting activation of ezrin by
adenosine. Furthermore, our data suggest that the activation of ezrin
is not merely because of an increase in cAMP but rather A2bR-mediated
as forskolin, which increases cAMP by activating adenylate cyclase,
does not increase E3KARP-ezrin interaction (25). Ezrin is present in
cells in both active and inactive states. The inactive state of ezrin
precludes its binding to its partners, NHERF-1, E3KARP, and the actin
cytoskeleton. The activation of ezrin is thought to be secondary to
phosphorylation of a COOH-terminal threonine (24). The mechanism of
ezrin activation by adenosine is intriguing and to our knowledge, this
is the first evidence of receptor-mediated direct activation of ezrin.
In summary, we show that the A2bR is recruited to the plasma membrane
upon agonist stimulation. The A2bR, in response to agonist stimulation,
interacts with E3KARP, ezrin, and PKA (Fig.
7). We speculate that such an interaction
not only anchors the receptor in the plasma membrane but functions to
stabilize the receptor in a signaling complex in the membrane
microdomain that defines the chloride secretory response to
adenosine.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Schematic representation of A2b trafficking
and its interaction with E3KARP. The figure shows that neutrophils
release 5'-AMP which is then converted into adenosine by epithelial
ectonucleotidase (CD 73). The adenosine then interacts with A2bR, a G
protein-coupled receptor, coupled to G s and increases
cAMP. Upon stimulation, the receptor is recruited to the
plasma membrane where it interacts with E3KARP, which in turn is
associated with ezrin. Ezrin on one hand interacts with actin
cytoskeleton and on the other hand acts as a protein kinase A anchoring
protein. Protein kinase A is activated by A2bR-mediated increase in
cAMP. PKA phosphorylates CFTR activating chloride secretion.
|
|
 |
ACKNOWLEDGEMENTS |
We thank Dr. Laura Volpicelli for assisting
with quantitation of confocal images and Dr. Guy Benian and Baljit
Walia for critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants K08 DK02802 (to S. V. S.), K01 DK 02831 (to D. M.), DK 35932 and DK 47662 (to J. L. M.), and the Deutsche
Forschungsgemeinschaft (to M. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. E-mail:
ssitar2@emory.edu.
Published, JBC Papers in Press, June 21, 2002, DOI 10.1074/jbc.M202522200
2
S. V. Sitaraman, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
PKA, protein
kinase A;
CFTR, cystic fibrosis transmembrane conductance regulator;
A2bR, adenosine 2b receptor;
GFP, green fluorescent protein;
CHO, Chinese hamster ovary;
CD 73, 5'-ectonucleotidase;
HBSS, Hank's
balanced salt solution.
 |
REFERENCES |
| 1.
|
Olah, M. E.,
and Stiles, G. L.
(1995)
Annu. Rev. Pharmacol. Toxicol.
35,
581-606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Feoktistov, I.,
and Biaggioni, I.
(1995)
J. Clin. Invest.
96,
1979-1986[Medline]
[Order article via Infotrieve]
|
| 3.
|
Feoktistov, I.,
and Biaggioni, I.
(1997)
Pharmacol. Rev.
49,
381-402[Abstract/Free Full Text]
|
| 4.
|
Linden, J.,
Auchampach, J. A.,
Xiaowei, J.,
and Figler, R. A.
(1995)
Life Sci.
62,
1519-1524
|
| 5.
|
Roman, R. M.,
and Fitz, J. G.
(1999)
Gastroenterologia
116,
964-979
|
| 6.
|
Van Belle, H.,
Gossens, F.,
and Wynants, J.
(1987)
Am. J. Physiol.
252,
H886-H893[Abstract/Free Full Text]
|
| 7.
|
Zidek, Z.
(1999)
Eur. Cytokine Netw.
10,
319-328[Medline]
[Order article via Infotrieve]
|
| 8.
|
Nash, S.,
Parkos, C.,
Nusrat, A.,
Delp, C.,
and Madara, J. L.
(1991)
J. Clin. Invest.
87,
1474-1477[Medline]
[Order article via Infotrieve]
|
| 9.
|
Madara, J. L.,
Patapoff, T. W.,
Gillece-Castro, B.,
Colgan, S.,
Parkos, C.,
Delp, C.,
and Mrsny, R.
(1993)
J. Clin. Invest.
91,
5716-5723
|
| 10.
|
Strohmeier, G. R.,
Reppert, S. M.,
Lencer, W. I.,
and Madara, J. L.
(1995)
J. Biol. Chem.
270,
2387-2394[Abstract/Free Full Text]
|
| 11.
|
Strohmeier, G. R.,
Lencer, W. I.,
Thompson, L. F.,
Carlson, S. L.,
Moe, S. J.,
Carnes, D. K.,
Mrsny, R. J.,
and Madara, J. L.
(1997)
J. Clin. Invest.
99,
2588-2601[Medline]
[Order article via Infotrieve]
|
| 12.
|
Palmer, T. M.,
and Stiles, G. L.
(1995)
Neuropharmacology
34,
683-694[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Ralevic, V.,
and Burnstock, G.
(1998)
Pharmacol. Rev.
50,
413-492[Abstract/Free Full Text]
|
| 14.
|
Christofi, F. L.,
Zhang, H., Yu, J. G.,
Guzman, J.,
Xue, J.,
Kim, M.,
Wang, Y. Z.,
and Cooke, H. J.
(2001)
J. Comp. Neurol.
439,
46-64[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Barrett, K. E.,
Cohn, J. A.,
Huott, P. A.,
Wasserman, S. I.,
and Dharmsathaphorn, K.
(1990)
Am. J. Physiol.
258,
C902-C912[Abstract/Free Full Text]
|
| 16.
|
Barrett, K. E.,
Huott, P. A.,
Shah, S.,
and Dharmasathaphorn, K.
(1989)
Am. J. Physiol.
256,
C197-C203[Abstract/Free Full Text]
|
| 17.
|
Sitaraman, S. V.,
Merlin, D.,
Wang, L.,
Wong, M.,
Gewirtz, A. T., Si-,
Tahar, M.,
and Madara, J. L.
(2001)
J. Clin. Invest.
107,
861-869[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Sitaraman, S. V., Si-,
Tahar, M.,
Merlin, D.,
Strohmeier, G. R.,
and Madara, J. L.
(2000)
Am. J. Physiol.
278,
C1230-C1236[Abstract/Free Full Text]
|
| 19.
|
Huang, P.,
Lazarowski, E. R.,
Tarran, R.,
Milgram, S. L.,
Boucher, R. C.,
and Stutts, M. J.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
14120-14125[Abstract/Free Full Text]
|
| 20.
|
Sheng, M.,
and Sala, C.
(2001)
Annu. Rev. Neurosci.
24,
1-29[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Sun, F.,
Hug, M. J.,
Lewarchik, C. M.,
Yun, C. H.,
Bradbury, N. A.,
and Frizzell, R. A.
(2000)
J. Biol. Chem.
275,
29539-29546[Abstract/Free Full Text]
|
| 22.
|
Hall, R. A.,
Premont, R. T.,
Chow, C. W.,
Blitzer, J. T.,
Pitcher, J. A.,
Claing, A.,
Stoffel, R. H.,
Barak, L. S.,
Shenolikar, S.,
Weinman, E. J.,
Grinstein, S.,
and Lefkowitz, R. J.
(1998)
Nature
392,
626-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Sun, F.,
Hug, M. J.,
Bradbury, N. A.,
and Frizzell, R. A.
(2000)
J. Biol. Chem.
275,
14360-14366[Abstract/Free Full Text]
|
| 24.
|
Bretscher, A.,
Chambers, D.,
Nguyen, R.,
and Reczek, D.
(2000)
Annu. Rev. Cell Dev. Biol.
16,
113-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Yun, C. H.,
Lamprecht, G.,
Forster, D. V.,
and Sidor, A.
(1998)
J. Biol. Chem.
273,
25856-26863[Abstract/Free Full Text]
|
| 26.
|
Merlin, D., Si-,
Tahar, M.,
Sitaraman, S. V.,
Eastburn, K.,
Williams, I.,
Liu, X.,
Hediger, M. A.,
and Madara, J. L.
(2001)
Gastroenterology
120,
1666-1679[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Smart, E. J.,
Ying, Y. S.,
Mineo, C.,
and Anderson, R. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10104-10108[Abstract/Free Full Text]
|
| 28.
|
Merlin, D.,
Sitaraman, S.,
Liu, X.,
Eastburn, K.,
Sun, J.,
Kucharzik, T.,
Lewis, B.,
and Madara, J. L.
(2001)
J. Biol. Chem.
276,
39282-39289[Abstract/Free Full Text]
|
| 29.
|
Volpicelli, L. A.,
Lah, J. J.,
and Levey, A. I.
(2001)
J. Biol. Chem.
276,
47590-47598[Abstract/Free Full Text]
|
| 30.
|
McCormick, B. A.,
Nusrat, A.,
Parkos, C. A.,
D'Andrea, L.,
Hofman, P. M.,
Carnes, D.,
Liang, T. W.,
and Madara, J. L.
(1997)
Infect. Immun.
65,
1414-1421[Abstract]
|
| 31.
|
Ellis, J. A.,
Jackman, M. R.,
and Luzio, J. P.
(1992)
Biochem. J.
283,
553-560
|
| 32.
|
Herrera, C.,
Casadó, V.,
Ciruela, F.,
Schofield, P.,
Mallol, J.,
Lluis, C.,
and Franco, R.
(2001)
Mol. Pharmacol.
59,
127-134[Abstract/Free Full Text]
|
| 33.
|
Peyot, M. L.,
Gadeau, A. P.,
Dandre, F.,
Belloc, I.,
Dupuch, F.,
and Desgranges, C.
(2000)
Circ. Res.
86,
76-85[Abstract/Free Full Text]
|
| 34.
|
Jacobson, M. A.,
Johnson, R. G.,
Luneau, C. J.,
and Salvatore, C. A.
(1995)
Genomics
27,
374-376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Linden, J.,
Thai, T.,
Figler, H.,
Jin, X.,
and Robeva, A. S.
(1999)
Mol. Pharmacol.
56,
705-713[Abstract/Free Full Text]
|
| 36.
|
Puffinbarger, N. K.,
Hansen, K. R.,
Resta, R.,
Laurent, A. B.,
Knudsen, T. B.,
Madara, J. L.,
and Thompson, L. F.
(1995)
Mol. Pharmacol.
47,
1126-1132[Abstract]
|
| 37.
|
Lasley, R. D.,
Narayan, P.,
Uittenbogaard, A.,
and Smart, E. J.
(2000)
J. Biol. Chem.
275,
4417-4421[Abstract/Free Full Text]
|
| 38.
|
Bradbury, N. A.,
and Bridges, R. J.
(1994)
Am. J. Physiol.
267,
C1-C24[Abstract/Free Full Text]
|
| 39.
|
Peters, K. W., Qi, J.,
Watkins, S. C.,
and Frizzell, R. A.
(2000)
Med. Clin. North Am.
84,
633-640[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Cheng, J.,
Moyer, B. D.,
Milewski, M.,
Loffing, J.,
Ikeda, M.,
Mickle, J. E.,
Cutting, G. R., Li, M.,
Stanton, B. A.,
and Guggino, W. B.
(2002)
J. Biol. Chem.
277,
3520-3529[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. L. Hart, M. Henn, D. Kohler, D. Kloor, M. Mittelbronn, I. C. Gorzolla, G. L. Stahl, and H. K. Eltzschig
Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury
FASEB J,
August 1, 2008;
22(8):
2784 - 2797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ryzhov, R. Zaynagetdinov, A. E. Goldstein, S. V. Novitskiy, M. M. Dikov, M. R. Blackburn, I. Biaggioni, and I. Feoktistov
Effect of A2B Adenosine Receptor Gene Ablation on Proinflammatory Adenosine Signaling in Mast Cells
J. Immunol.,
June 1, 2008;
180(11):
7212 - 7220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Wang, Y. Sun, W. Zhang, and P. Huang
Apical adenosine regulates basolateral Ca2+-activated potassium channels in human airway Calu-3 epithelial cells
Am J Physiol Cell Physiol,
June 1, 2008;
294(6):
C1443 - C1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ryzhov, R. Zaynagetdinov, A. E. Goldstein, S. V. Novitskiy, M. R. Blackburn, I. Biaggioni, and I. Feoktistov
Effect of A2B Adenosine Receptor Gene Ablation on Adenosine-Dependent Regulation of Proinflammatory Cytokines
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
694 - 700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hayashi, N. Okino, Y. Kakuta, T. Shikanai, M. Tani, H. Narimatsu, and M. Ito
Klotho-related Protein Is a Novel Cytosolic Neutral beta-Glycosylceramidase
J. Biol. Chem.,
October 19, 2007;
282(42):
30889 - 30900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Donowitz and X. Li
Regulatory Binding Partners and Complexes of NHE3
Physiol Rev,
July 1, 2007;
87(3):
825 - 872.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Theiss, T. S. Obertone, D. Merlin, and S. V. Sitaraman
Interleukin-6 Transcriptionally Regulates Prohibitin Expression in Intestinal Epithelial Cells
J. Biol. Chem.,
April 27, 2007;
282(17):
12804 - 12812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, S. Srinivasan, A. L. Theiss, D. Merlin, and S. V. Sitaraman
Interleukin-6 Induces Keratin Expression in Intestinal Epithelial Cells: POTENTIAL ROLE OF KERATIN-8 IN INTERLEUKIN-6-INDUCED BARRIER FUNCTION ALTERATIONS
J. Biol. Chem.,
March 16, 2007;
282(11):
8219 - 8227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Theiss, R. D. Idell, S. Srinivasan, J.-M. Klapproth, D. P. Jones, D. Merlin, and S. V. Sitaraman
Prohibitin protects against oxidative stress in intestinal epithelial cells
FASEB J,
January 1, 2007;
21(1):
197 - 206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. D. Holliday, C.-W. Lam, I. R. Tough, and H. M. Cox
Role of the C Terminus in Neuropeptide Y Y Receptor Desensitization and Internalization
Mol. Pharmacol.,
March 1, 2005;
67(3):
655 - 664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Kolachala, V. Asamoah, L. Wang, S. Srinivasan, D. Merlin, and S. V. Sitaraman
Interferon-{gamma} Down-regulates Adenosine 2b Receptor-mediated Signaling and Short Circuit Current in the Intestinal Epithelia by Inhibiting the Expression of Adenylate Cyclase
J. Biol. Chem.,
February 11, 2005;
280(6):
4048 - 4057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shenolikar, J. W. Voltz, R. Cunningham, and E. J. Weinman
Regulation of Ion Transport by the NHERF Family of PDZ Proteins
Physiology,
December 1, 2004;
19(6):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, V. Kolachala, B. Walia, S. Balasubramanian, R. A. Hall, D. Merlin, and S. V. Sitaraman
Agonist-induced polarized trafficking and surface expression of the adenosine 2b receptor in intestinal epithelial cells: role of SNARE proteins
Am J Physiol Gastrointest Liver Physiol,
November 1, 2004;
287(5):
G1100 - G1107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hague, M. A. Uberti, Z. Chen, C. F. Bush, S. V. Jones, K. J. Ressler, R. A. Hall, and K. P. Minneman
Olfactory receptor surface expression is driven by association with the {beta}2-adrenergic receptor
PNAS,
September 14, 2004;
101(37):
13672 - 13676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hague, M. A. Uberti, Z. Chen, R. A. Hall, and K. P. Minneman
Cell Surface Expression of {alpha}1D-Adrenergic Receptors Is Controlled by Heterodimerization with {alpha}1B-Adrenergic Receptors
J. Biol. Chem.,
April 9, 2004;
279(15):
15541 - 15549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Bucheimer and J. Linden
Purinergic regulation of epithelial transport
J. Physiol.,
March 1, 2004;
555(2):
311 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Sneddon, C. A. Syme, A. Bisello, C. E. Magyar, M. D. Rochdi, J.-L. Parent, E. J. Weinman, A. B. Abou-Samra, and P. A. Friedman
Activation-independent Parathyroid Hormone Receptor Internalization Is Regulated by NHERF1 (EBP50)
J. Biol. Chem.,
October 31, 2003;
278(44):
43787 - 43796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, B. Walia, J. Evans, A. T. Gewirtz, D. Merlin, and S. V. Sitaraman
IL-6 Induces NF-{kappa}B Activation in the Intestinal Epithelia
J. Immunol.,
September 15, 2003;
171(6):
3194 - 3201.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|